Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review. (Q54001527)

23 May 2018

title

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review. (English)

1 reference

23 May 2018

obsessive-compulsive disorder

main subject

1 reference

1 reference

J A Den Boer

1

1 reference

23 May 2018

H G M Westenberg

series ordinal

2

1 reference

23 May 2018

publication date

1 October 1995

1 reference

23 May 2018

published in

Human Psychopharmacology

1 reference

23 May 2018

volume

10 Suppl 3

1 reference

23 May 2018

issue

S3

1 reference

23 May 2018

page(s)

S173-S183

1 reference

23 May 2018

Zimelidine - a serotonin uptake blocker in the treatment of phobic anxiety.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Comparison of buspirone and diazepam in generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Psychiatric reaction patterns to imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Treatment of spontaneous panic attacks with chlomipramine

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

DELINEATION OF TWO DRUG-RESPONSIVE ANXIETY SYNDROMES

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Antidepressant drugs in anxiety disorders.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Serotonin autoreceptor subsensitivity and antidepressant activity

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Long-term follow-up of 85 patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Discontinuation reactions to alprazolam in panic disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Fluvoxamine treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Clinical Studies of Buspirone

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

The relative efficacy of buspirone, imipramine and placebo in panic disorder: A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FHUP.470100906

7 January 2021

Identifiers

DOI

10.1002/HUP.470100906

1 reference

23 May 2018

1 reference

23 May 2018